Summary of Key Points Core Viewpoint - The article discusses the stock buyback activities of various companies, highlighting the amounts repurchased and their significance in terms of total shares outstanding. Group 1: Major Buybacks - Tencent Holdings (00700) had the largest buyback, repurchasing 1.044 million shares for a total of 636 million [1][2] - China Merchants Industry Holdings (01919) repurchased 4.461 million shares for 60.86 million, representing 2.986% of its total shares [2] - Geely Automobile (00175) bought back 1.362 million shares for 23.92 million, which is 0.078% of its total shares [2] Group 2: Notable Buyback Activities - China Feihe (06186) repurchased 5.655 million shares for 23.18 million, accounting for 2.605% of its total shares [2] - Yum China (09987) conducted two buybacks totaling 58,000 shares for 21.67 million, representing 4.750% of its total shares [2] - Kweichow Moutai (01951) repurchased 772,200 shares for 19.35 million, which is 0.280% of its total shares [2] Group 3: Other Companies Involved - Vitasoy International (00345) repurchased 2,000 shares for 13,300, which is 2.209% of its total shares [3] - Yanzhiyu (01497) bought back 200,000 shares for 1.39 million, representing 0.786% of its total shares [3] - Weigao Group (01066) repurchased 120,000 shares for 631,000, which is 5.179% of its total shares [3]

Summary of Key Points Core Viewpoint - 康臣药业 has been actively repurchasing its shares, indicating a strategy to support its stock price amidst recent declines [1][2]. Group 1: Share Buyback Activity - On December 12, 康臣药业 repurchased 231,000 shares at a price range of HKD 14.760 to HKD 14.970, totaling HKD 3.4373 million [1]. - The stock closed at HKD 14.870 on the same day, reflecting a decrease of 0.87%, with total trading volume of HKD 17.2563 million [1]. - Since December 10, the company has conducted buybacks for three consecutive days, accumulating a total of 726,000 shares and a total expenditure of HKD 10.8264 million, during which the stock price fell by 0.93% [1]. Group 2: Year-to-Date Buyback Summary - Year-to-date, 康臣药业 has executed 55 buyback transactions, acquiring a total of 13.182 million shares for a cumulative amount of HKD 178 million [2]. - The detailed buyback data shows various transactions with the highest buyback price reaching HKD 15.840 and the lowest at HKD 11.000 [3].

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Group 1: Share Buyback Details - The company plans to repurchase 231,000 shares at a total cost of HKD 3.4373 million [1] - The buyback price per share ranges from HKD 14.76 to HKD 14.97 [1]

Group 1 - The company, 康臣药业 (01681), announced a share buyback on December 12, 2025, spending HKD 3.4373 million to repurchase 231,000 shares [1] - The buyback price per share ranged from HKD 14.76 to HKD 14.97 [1]

Core Viewpoint - Kangchen Pharmaceutical (01681.HK) announced a share buyback on December 12, 2023, spending HKD 3.437 million to repurchase 231,000 shares at a price range of HKD 14.76 to 14.97 per share [1] Group 1 - The company executed a buyback of 231,000 shares [1] - The total expenditure for the buyback was HKD 3.437 million [1] - The buyback price per share ranged from HKD 14.76 to 14.97 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康臣葯業集團有限公司 呈交日期： 2025年12月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | | 是 | | | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | | | 已發行股份（不包括庫存 ...

康臣药业(01681.HK)公告，12月11日耗资211.2万港元回购14.1万股，回购价格每股14.9-15港元。 本文源自：格隆汇 ...

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Company Actions - 康臣药业 plans to repurchase 141,000 shares at a total cost of HKD 2.1118 million [1] - The buyback price is set between HKD 14.9 and HKD 15.0 per share [1]

公司名稱： 康臣葯業集團有限公司 呈交日期： 2025年12月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on December 10, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Companies with Significant Buybacks - Tencent Holdings (00700) repurchased 1.06 million shares for a total of 636 million, representing 0.961% of its total share capital [2] - Xiaomi Group-W (01810) repurchased 2.4 million shares for 101 million, accounting for 0.400% of its total share capital [2] - China Feihe (06186) repurchased 5.47 million shares for 22.94 million, which is 2.521% of its total share capital [2] Group 2: Other Notable Buybacks - Geely Automobile (00175) repurchased 1.54 million shares for 27.14 million, representing only 0.047% of its total share capital [2] - Kweichow Moutai (600519) repurchased 204,000 shares for 8.82 million, which is 0.180% of its total share capital [2] - Vitasoy International (00345) repurchased 404,000 shares for 2.67 million, accounting for 2.180% of its total share capital [2] Group 3: Companies with Lower Buyback Amounts - 康臣药业 (01681) repurchased 354,000 shares for 5.28 million, which is 15.048% of its total share capital [2] - 瑞声科技 (02018) repurchased 150,000 shares for 5.76 million, representing 0.492% of its total share capital [2] - 周黑鸭 (01458) repurchased 160,500 shares for 2.68 million, which is 1.407% of its total share capital [3]